Form 4: Protagonist Therapeutics CEO Awarded Stock and Options
SEC Form 4 Filing
Protagonist Therapeutics CEO, Dinesh V. Patel, Ph.D., received a grant of restricted stock units and stock options on January 2, 2025.
Summary
- Dinesh V. Patel, the President and CEO of Protagonist Therapeutics, Inc., was granted 149,800 restricted stock units and 181,472 stock options on January 2, 2025.
- The restricted stock units will vest in four equal annual installments starting January 15, 2026, and continuing through 2029, contingent on continued service.
- The stock options will vest in 48 equal monthly installments following January 2, 2025, also contingent on continued service.
- The exercise price for the stock options is $38.98.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally positive for aligning management interests with shareholders. There are no indications of negative sentiment.
Positives
- The grant of stock and options aligns the CEO's interests with the long-term success of the company.
- The vesting schedules for both the stock units and options incentivize continued service and performance from the CEO.
Risks
- The value of the stock options is dependent on the future performance of the company's stock price.
- The vesting of both the stock units and options is contingent on the CEO's continued service, creating a potential risk if he were to leave the company.
Industry Context
The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants and restricted stock units are standard forms of compensation for CEOs in the biotech industry.
- The vesting schedules described are typical for executive compensation packages, designed to align executive interests with long-term company performance.
- Comparable companies in the biotech sector often use similar equity-based compensation structures to attract and retain top talent.
Stakeholder Impact
- Shareholders may view the stock and option grants as a positive sign of management's commitment to the company's long-term success.
- Employees may see this as a positive sign of the company's financial health and commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of grant for restricted stock units and stock options. |
| 01/06/2025 | Date of signature for the SEC Form 4 filing. |
| 01/15/2026 | First vesting date for restricted stock units. |
| 01/15/2027 | Second vesting date for restricted stock units. |
| 01/15/2028 | Third vesting date for restricted stock units. |
| 01/15/2029 | Final vesting date for restricted stock units. |
| 01/02/2035 | Expiration date for the stock options. |
Keywords
stock options, restricted stock units, executive compensation, insider trading, Protagonist Therapeutics, PTGX, CEO, Dinesh V. Patel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.